Guiding clinical decisions in personalized cancer therapy by assessing cell signaling aberrations
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world with almost 200 new cases per year in Norway. Although novel therapies have been developed, the disease remains incurable. The incidence rate rises with age, thus the prevalence and mortality of CLL are likely to increase further due to demographic changes in society in the forthcoming decades
Aim: In collaboration with Oslo University Hospital, Rikshospitalet, we aim to develop a fast (3-4 days from sampling to test result) strategy to assist clinical decisions in personalized cancer therapy (Figure 1).
Approach: Phosphoflow cytometry will be applied for high-throughput and rapid signaling analysis. Results will identify aberrant signaling patterns in CLL for the indication of drug targets in the individual patient. We will investigate the effects of drugs and drug combinations on both signaling and cell killing in order to identify predictive biomarkers for each drug, as well as synergistic drug combinations.
Published Apr. 19, 2018 8:13 AM
- Last modified Feb. 7, 2020 5:00 PM
Scope (credits)
60
Master project in the group of:
Professor dr.med Kjetil Taskén, Norwegian Center for Molecular Medicine (NCMM), University of Oslo
Supervised by Sigrid S Skånland, Researcher, PhD
http://www.med.uio.no/ncmm/english/groups/tasken-group/